Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

The University of Texas Health Science Center, Houston99 enrolled

Overview

To correlate the Human Leukocyte Antigen type and genetic defect with hemophilia A.

One of the most serious complications of treatment in patients with hemophilia A or hemophilia B is the development of an inhibitor, which is an antibody that neutralizes the factor VIII or IX coagulant activity. Up to one fourth of patients with severe hemophilia A develop an inhibitor but at present it is not possible to predict which patients will develop such antibody. The ability to predict an inhibitor development at an individual level would greatly improve therapeutic approach to this serious problem

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hemophilia A

Eligibility

Sex: MALEMin age: 1 DayMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Severe Hemophilia A with an inhibitor level of 0.6 B.U. or higher Exclusion Criteria: * Severe Hemophilia A with a negative inhibitor

Locations (1)

The Univeristy of Texas Health Science Center at Houston

Houston, Texas, United States

Outcomes

Primary Outcomes

Inactivation of antibodies by the FVIII covalent reactive analogs

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.